Livforsakringsbolaget Skandia Omsesidigt decreased its position in Eli Lilly and Co (NYSE:LLY) by 15.0% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 26,717 shares of the company’s stock after selling 4,700 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Eli Lilly and were worth $2,257,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of LLY. Acrospire Investment Management LLC grew its holdings in shares of Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC bought a new position in shares of Eli Lilly and in the second quarter worth approximately $128,000. San Francisco Sentry Investment Group CA bought a new position in shares of Eli Lilly and in the second quarter worth approximately $129,000. Willingdon Wealth Management bought a new position in shares of Eli Lilly and in the third quarter worth approximately $138,000. Finally, Wealthcare Advisory Partners LLC bought a new position in shares of Eli Lilly and in the third quarter worth approximately $142,000. Hedge funds and other institutional investors own 76.35% of the company’s stock.

Eli Lilly and Co (NYSE LLY) opened at $85.82 on Friday. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $94,925.41, a price-to-earnings ratio of 40.67, a price-to-earnings-growth ratio of 1.68 and a beta of 0.35. Eli Lilly and Co has a 52-week low of $74.00 and a 52-week high of $89.09.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.88 earnings per share. equities research analysts forecast that Eli Lilly and Co will post 4.22 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a dividend of $0.5625 per share. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 annualized dividend and a yield of 2.62%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio (DPR) is currently 98.58%.

Several research analysts have recently issued reports on LLY shares. Credit Suisse Group cut shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and raised their target price for the stock from $84.23 to $88.00 in a report on Tuesday, October 10th. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price target for the company in a research note on Thursday, October 26th. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the stock a “sell” rating in a research note on Wednesday, November 1st. Morgan Stanley raised their price target on Eli Lilly and from $86.00 to $90.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 21st. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a research note on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $92.75.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the completion of the transaction, the insider now owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold 251,088 shares of company stock valued at $22,041,236 in the last three months. Insiders own 0.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/01/19/livforsakringsbolaget-skandia-omsesidigt-sells-4700-shares-of-eli-lilly-and-co-lly.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.